| Document |
Document Title |
|
WO/2019/104030A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
|
|
WO/2019/090069A1 |
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/085847A1 |
Disclosed are a Piper laetispicum extract and a preparation method therefor and a use thereof. The Piper laetispicum extract comprises any one of sesamin, (2E, 6E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)heptadienamide, (2E, 4E)-N-isobuty...
|
|
WO/2019/079119A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3
|
|
WO/2019/068772A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic ...
|
|
WO/2019/060994A1 |
Compounds, compositions and their use in the treatment or prevention of symptoms of Lowe Syndrome and Dent disease 2 are described, for instance, the use of such compounds in the treatment of Lowe Syndrome and Dent disease 2, or in the t...
|
|
WO/2019/060210A1 |
The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly diso...
|
|
WO/2019/056120A1 |
The present application relates to sulfonamide containing compounds of Formulae (I) and (II) and compositions containing said compounds effective in the treatment of cell proliferative disorders, in particular cancer, and various methods...
|
|
WO/2019/053634A1 |
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharma...
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/044476A1 |
This fluorine-containing bissulfonylimide compound is represented by general formula (1). In general formula (1), Rf1 represents an ether-bond-containing perfluoroalkyl group in which an ether bond is present and the number of carbon ato...
|
|
WO/2019/045035A1 |
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|
|
WO/2019/046287A1 |
The present invention includes compositions and methods for treating or preventing hepatitis B virus (HBV) infections in a patient.
|
|
WO/2019/044286A1 |
Provided is an efficient method for producing a perfluoroalkane sulfonylimide acid metal salt. The perfluoroalkane sulfonylimide acid metal salt is produced by: reacting a perfluoroalkane sulfonyl halide with an organic base and ammonia ...
|
|
WO/2019/043610A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2019/040122A1 |
This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain.
|
|
WO/2019/040380A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2019/034697A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom ...
|
|
WO/2019/031472A1 |
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...
|
|
WO/2019/029211A1 |
Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof, and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmac...
|
|
WO/2019/017814A9 |
The present invention relates to novel hepatitis B virus (HBV) inhibitors for use as chemotherapeutic agents for treating HBV. The compounds bind to HBV core-antigen and trigger the formation of aberrant virus capsids not carrying the vi...
|
|
WO/2019/032739A1 |
The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compo...
|
|
WO/2019/028343A1 |
Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided h...
|
|
WO/2019/025153A1 |
The invention relates to the use of substituted N-sulfonyl-N'-aryl diaminoalkanes and N-sulfonyl-N'-heteroaryl diaminoalkanes of general formula (I), or the salts thereof, formula (I), wherein the groups in general formula (I) are define...
|
|
WO/2019/026994A1 |
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...
|
|
WO/2019/022097A1 |
[Problem] To provide a sulfonyl azide benzoic acid derivative that can be used in a bioorthogonal click reaction. [Solution] The following sulfonyl azide benzoic acid derivative was developed as a compound to be used in a highly versatil...
|
|
WO/2019/009759A1 |
The present invention relates to a novel combined medicinal preparation having a solid oral dosage form and comprising as one of three active ingredients elsulfavirine sodium, which could be used in medicine for treating viral infections...
|
|
WO/2019/008061A1 |
The present invention relates to asymmetric sulfonamide compounds comprising at least: • one polycyclic group, Ar, formed of two to six rings, at least one of which is aromatic, • a linear or branched, saturated or unsaturated alipha...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/237163A1 |
Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria. In at least one specific embodiment, the 5-Aminolevulinate synthase inhibitors can include compounds or salts thereof of...
|
|
WO/2018/228857A1 |
The invention relates to novel laser markable compositions comprising developing agent precursors according to formula (I).
|
|
WO/2018/224560A1 |
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in p...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/215070A1 |
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...
|
|
WO/2018/215610A1 |
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...
|
|
WO/2018/215287A1 |
The invention relates to a color developer of formula (I), (Ar1-SO2-NH-)m-Y-(-NH-C(O)-NH-SO2-Ar2)n (I), wherein Ar1 is an unsubstituted or substituted aromatic moiety, Ar2 is an unsubstituted or substituted phenyl moiety, Y is at least a...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/212368A1 |
The present invention relates to a novel compound and a pharmaceutical composition, for preventing or treating degenerative neurological disorders, comprising the compound as an active ingredient. The novel compound, which is obtained by...
|
|
WO/2018/210729A1 |
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...
|
|
WO/2018/212216A1 |
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...
|
|
WO/2018/204987A1 |
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-can...
|
|
WO/2018/204775A1 |
A method for the treatment and/or reduction of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is disclosed. The method uses active amino-aryl-benzamide compounds and methods for the preparation thereof.
|
|
WO/2018/196677A1 |
The present invention relates to a fluoroallylamine derivative and the use thereof. In particular, the present invention relates to a compound as shown in formula I, a prodrug, an isomer, an isotopically labelled compound, a solvate or a...
|
|
WO/2018/188795A1 |
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.
|
|
WO/2018/186040A1 |
Provided is an ionic liquid, characterized in containing a cationic component and an anionic component, and in that the cationic component comprises a group having a perfluoropolyether chain and a group having a hydroxyl group.
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/181884A1 |
The objective of the present invention is to provide a novel compound inhibiting the entry of a filovirus into a cell, a medical composition, an anti-filovirus agent, or a filovirus entry inhibitor containing the compound, as well as a m...
|
|
WO/2018/179343A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/176134A1 |
The present disclosure relates to compounds for use as electrode additives or as salts in electrolyte compositions, and their methods of preparation. The majority of compounds are anions of imidazoles bearing a sulphonyl or a carbonyl gr...
|
